DDInter258 DDInter905
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Pentazocine
Pentazocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Baricitinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Buprenorphine
Buprenorphine {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Pentazocine
Pentazocine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Dezocine
Dezocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Satralizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Idelalisib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Butorphanol (Compound) resembles Pentazocine (Compound) and Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Butorphanol (Compound) resembles Buprenorphine (Compound) and Buprenorphine (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Butorphanol (Compound) resembles Pentazocine (Compound) and Pentazocine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Butorphanol (Compound) resembles Dezocine (Compound) and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib